188826-32-6

Basic information

• Product Name: 5-Fluoro-4-chromanone
• Synonyms: 5-Fluoro-4-chromanone;5-Fluorochroman-4-one;5-fluoro-2,3-dihydrochromen-4-one
• CAS NO: 188826-32-6
• Molecular Formula: C9H7FO2
• Molecular Weight: 166.1490832
• Mol File: 188826-32-6.mol

Chemical Properties

• Boiling Point: 279.991 °C at 760 mmHg
• Flash Point: 119.357 °C
• Appearance: /
• Density: 1.298 g/cm³
• Refractive Index: 1.54
• CAS DataBase Reference: 5-Fluoro-4-chromanone(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluoro-4-chromanone(188826-32-6)
• EPA Substance Registry System: 5-Fluoro-4-chromanone(188826-32-6)

Safety Data

• Hazardous Substances Data: 188826-32-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-Fluoro-4-chromanone is utilized as a key building block in the development of novel pharmaceutical compounds due to its unique chemical properties and potential biological activities.
Used in Anticancer Research:
In the field of oncology, 5-Fluoro-4-chromanone is employed as a potential anti-cancer agent, leveraging its biological activities to target and combat cancer cells.
Used in Anti-inflammatory Applications:
5-Fluoro-4-chromanone is used as an anti-inflammatory agent, capitalizing on its ability to reduce inflammation which can be beneficial in treating various inflammatory conditions.
Used in Antioxidant Formulations:
5-Fluoro-4-chromanone is also used in antioxidant formulations to protect cells from oxidative stress, which is implicated in numerous diseases and aging processes.
Used in Medicinal Chemistry Research:
5-Fluoro-4-chromanone serves as a valuable tool in medicinal chemistry research, aiding scientists in understanding its structure-activity relationships and optimizing its therapeutic potential.
Used in Drug Discovery:
In the realm of drug discovery, 5-Fluoro-4-chromanone is applied to identify and develop new drug molecules with improved efficacy and safety profiles for the treatment of various diseases.

InChI:InChI=1/C9H7FO2/c10-6-2-1-3-8-9(6)7(11)4-5-12-8/h1-3H,4-5H2

Upstream product

• 133077-43-7 C₉H₈ClFO₂ 
• 133077-42-6 3-(3-fluorophenoxy)propanoic acid 
• 844648-05-1 3-(3-fluorophenoxy)propanenitrile 
• 372-20-3 3-fluorophenol 
• 2967-72-8 3-(2-fluorophenoxy)propanoic acid 
• 145073-40-1 3-(2-fluorophenoxy)-1-propanol 
• 367-12-4 2-fluorophenol 

Downstream Products

• 1630952-72-5 8-(5-fluorochroman-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 

Relevant articles and documents

Synthesis, enantiomeric separation and docking studies of spiropiperidine analogues as ligands of the nociceptin/orphanin FQ receptor

A series of triazospirodecanone derivatives were synthesized as potential NOP ligands. 8-(Chroman-4-yl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (4) and its 5-fluoro analogue (18) proved to be active as agonists with EC50 values in the submicromolar range. Single enantiomers of compound 4 were separated and tested as NOP agonists; the eutomer R-(+)-4 showed a pEC 50 of 7.34. Finally docking studies were performed on the NOP receptor to identify the most significant stereospecific interactions.

Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application

The design and synthesis of novel HIV-1 protease inhibitors (PIs) (1-22), which display high potency against HIV-1 wild-type and multi-PI-resistant HIV-mutant clinical isolates, is described. Lead optimization was initiated from compound 1, a Phe-Phe hydroxyethylene peptidomimetic PI, and was directed towards the discovery of new PIs suitable for a long-acting (LA) injectable drug application. Introducing a heterocyclic 6-methoxy-3-pyridinyl or a 6-(dimethylamino)-3-pyridinyl moiety (R3) at the para-position of the P1′ benzyl fragment generated compounds with antiviral potency in the low single digit nanomolar range. Halogenation or alkylation of the metabolic hot spots on the various aromatic rings resulted in PIs with high stability against degradation in human liver microsomes and low plasma clearance in rats. Replacing the chromanolamine moiety (R1) in the P2 protease binding site by a cyclopentanolamine or a cyclohexanolamine derivative provided a series of high clearance PIs (16-22) with EC50s on wild-type HIV-1 in the range of 0.8-1.8 nM. PIs 18 and 22, formulated as nanosuspensions, showed gradual but sustained and complete release from the injection site over two months in rats, and were therefore identified as interesting candidates for a LA injectable drug application for treating HIV/AIDS.

SPIROAMINODIHYDROTHIAZINE DERIVATIVES

A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an Aβ production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ and typified by Alzheimer- type dementia.